AbbVie Inc. (ABBV) FY2025 Annual P&L / Income Statement

AbbVie Inc. (ABBV) FY2025 Annual P&L / Income Statement

Income statement for 2025-01-01 through 2025-12-31. View: Key Product Portfolio by Product and Service. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Net revenues

61,160,000,000 US dollars

Cost of products sold

18,204,000,000 US dollars

Gross profit (calculated)

42,956,000,000 US dollars

Operating expenses (calculated)

27,881,000,000 US dollars

Operating earnings

15,075,000,000 US dollars

Other income (expense), net (calculated)

negative 8,478,000,000 US dollars

Earnings before income tax expense

6,597,000,000 US dollars

Income tax expense (benefit)

2,364,000,000 US dollars

Net earnings

4,233,000,000 US dollars

Aesthetics - Botox Cosmetic

2,602,000,000 US dollars

Aesthetics - Juvederm Collection

993,000,000 US dollars

Aesthetics - Other Aesthetics

1,265,000,000 US dollars

Eye Care - Alphagan/Combigan

197,000,000 US dollars

Eye Care - Lumigan/Ganfort

410,000,000 US dollars

Eye Care - Other Eye Care

1,009,000,000 US dollars

Eye Care - Ozurdex

493,000,000 US dollars

Immunology - Humira

4,540,000,000 US dollars

Immunology - Rinvoq

8,304,000,000 US dollars

Immunology - Skyrizi

17,562,000,000 US dollars

Neuroscience - Botox Therapeutic

3,769,000,000 US dollars

Neuroscience - Duodopa

381,000,000 US dollars

Neuroscience - Other Neuroscience

207,000,000 US dollars

Neuroscience - Qulipta

1,036,000,000 US dollars

Neuroscience - Ubrelvy

1,271,000,000 US dollars

Neuroscience - Vraylar

3,621,000,000 US dollars

Neuroscience - Vyalev

482,000,000 US dollars

Oncology - Elahere

690,000,000 US dollars

Oncology - Epkinly

271,000,000 US dollars

Oncology - Imbruvica

2,869,000,000 US dollars

Oncology - Venclexta

2,792,000,000 US dollars

Other Key Products - Linzess/Constella

907,000,000 US dollars

Other Key Products - Mavyret

1,317,000,000 US dollars

Undisclosed (calculated)

4,172,000,000 US dollars

Selling, general and administrative

14,010,000,000 US dollars

Research and development

9,096,000,000 US dollars

Acquired IPR&D and milestones

5,016,000,000 US dollars

Other operating income

negative 241,000,000 US dollars

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
• Of which attributable to AbbVie Inc.: $4.23 B; to noncontrolling interests: $7.00 M.